R
Robert Hamatake
Researcher at Research Triangle Park
Publications - 33
Citations - 1086
Robert Hamatake is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Hepatitis C virus & Replicon. The author has an hindex of 16, co-authored 33 publications receiving 967 citations.
Papers
More filters
Journal ArticleDOI
RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.
Cory Iverson,Gary Larson,Chon Lai,Li-Tain Yeh,Claudia Dadson,Paul Weingarten,Todd Appleby,Todd Vo,Andreas Maderna,Jean-Michel Vernier,Robert Hamatake,Jeffrey N. Miner,Barry D. Quart +12 more
TL;DR: Using pharmacokinetic and pharmacodynamic data, it is shown that maintaining adequate MEK inhibition throughout the dosing interval is likely more important than achieving high peak levels because greater efficacy was achieved with more frequent but lower dosing.
Journal ArticleDOI
Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase.
I. Wayne Cheney,Shunqi Yan,Todd Appleby,Heli Walker,Todd Vo,Nanhua Yao,Robert Hamatake,Zhi Hong,Jim Zhen Wu +8 more
TL;DR: A hydrogen bond matrix involving the Pim-1 inhibitor, two water molecules, and the catalytic core, together with a potential weak hydrogen bond between an aromatic hydrogen on the R(1) phenyl ring and a main-chain carbonyl of Pim -1 accounts for the overall potency of this inhibitor.
Journal ArticleDOI
Gene Expression Profiling Indicates the Roles of Host Oxidative Stress, Apoptosis, Lipid Metabolism, and Intracellular Transport Genes in the Replication of Hepatitis C Virus
Samantha L. Blackham,Andrew Baillie,Fadel Al-Hababi,Katja Remlinger,Shihyun You,Robert Hamatake,Michael J. McGarvey +6 more
TL;DR: Results show that major changes in the expression of many different genes in target cells may be crucial in determining the outcome of HCV infection, and provide insight into the potential mechanisms that contribute to HCV-associated pathogenesis.
Journal ArticleDOI
Novel thiazolones as HCV NS5B polymerase allosteric inhibitors: Further designs, SAR, and X-ray complex structure
Shunqi Yan,Gary Larson,Jim Zhen Wu,Todd Appleby,Yili Ding,Robert Hamatake,Zhi Hong,Nanhua Yao +7 more
TL;DR: SAR explorations and further structure-based design led to the identifications of 2 and 3 as novel HCV NS5B inhibitors.
Journal ArticleDOI
Structure-based design of a novel thiazolone scaffold as HCV NS5B polymerase allosteric inhibitors.
TL;DR: A structure-based approach was performed to design a novel thiazolone scaffold as HCV NS5B inhibitors and one of the top-scored molecules was synthesized and shown to have similar potency to the initial hit.